Fueled by funding from the FSH Society, an international research team has discovered the genes that cause facioscapulohumeral muscular dystrophy (FSHD), a devastating muscle-wasting disease that affects 500,000 people around the world. The FSH Society answers questions about what these findings mean for patients.
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
Year-End Challenge to Fund the Treatment for FSHD! A group of long-time supporters have come forward to challenge the Society’s members and friends to make gifts to Fund the Treatment for FSHD. These generous donors will match your gift dollar for dollar, up to a total of $255,000, if you make your gift by December… Read More »
Canadian Foundation Launched! Great news for Canadians who wish to support FSHD research! Canadians can now donate funds directly towards FSHD research — and receive a tax deduction. The FSHD Canada Foundation and the FSH Society are pleased to work together to direct funding to the highest quality, most impactful research on FSHD
Exciting news to report! A watershed paper was published online in Nature Genetics identifying the mutation in a gene causing the non-chromosome-4-linked FSHD disease called FSHD1B or FSHD2